How effective is Adagrasib in treating KRAS G12C mutations?

Adagrasib is a targeted inhibitor targeting the KRAS G12C mutation. It has shown positive clinical prospects in the treatment of various malignant tumors such as non-small cell lung cancer (NSCLC). As one of the innovative drugs targeting the KRAS G12C target, the development of adagrasib marks that "undruggable" targets are gradually being conquered, providing new hope for patients who lacked effective treatments in the past.

KRAS G12C mutation is a common driver gene mutation, mainly found in solid tumors such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Among NSCLC patients, about 13% of adenocarcinoma patients carry KRAS G12C mutations, and most of them are closely related to smoking history. Because this mutation causes the KRAS protein to remain activated in tumor cells, thereby driving cell proliferation and inhibiting apoptosis, it has become one of the key directions of new drug research and development in recent years.

Adagrasib irreversibly binds to the cysteine residues of the KRAS G12C mutant protein, locking it in an inactive conformation, thereby blocking downstream signaling pathways (such as MAPK, PI3K, etc.) and inhibiting the proliferation of tumor cells. Clinical studies have shown that adagrasib has good pharmacokinetic properties, including a long half-life (about 24 hours) and high tissue penetration ability, allowing it to continuously act on the tumor microenvironment and improve the intensity and duration of target inhibition.

In Phase II clinical trials (such as the KRYSTAL-1 study), adagrasib is used in patients with KRAS who have previously received standard treatment. G12Cmutation-positiveNSCLC patients have shown encouraging efficacy data. Research results show that the objective response rate (ORR) of the drug is about 43%, and the disease control rate (DCR) is close to DCR an>80%, the median progression-free survival (PFS) is about 6.5 months, the median overall survival (OS) up to 12 months or more. This is already a significant therapeutic breakthrough for a group of patients who have previously had no effective targeted options.

In addition, adagrasib has been confirmed to have certain central nervous system (CNS) activity, can penetrate the blood-brain barrier, and may also be effective in patients with brain metastases. In the trial, some patients with brain metastases also experienced tumor shrinkage and disease control, providing new possibilities for the treatment of CNS metastasis in NSCLC.

The safety of adagrasiib is generally controllable. The most common adverse reactions include diarrhea, nausea, fatigue, vomiting, and elevated transaminases. Serious adverse events are relatively rare, but some patients still need to adjust the dose or suspend medication due to toxicity. In practical applications, doctors need to closely monitor the patient's liver function and gastrointestinal tolerance and reasonably arrange the medication rhythm.

In addition to its application in NSCLC, adagrasib is also being studied in multiple KRAS G12C mutation-related tumors, including colorectal cancer, pancreatic cancer, etc. In combination therapy studies such as KRYSTAL-10, adagrasib has been combined with immunotherapy, EGFR inhibitors and other drugs to show stronger anti-tumor activity, providing a direction for the optimization of subsequent treatment strategies.

In general, adagrasib has shown good efficacy and controllable safety in the treatment of KRAS G12C mutation-positive non-small cell lung cancer. It is a new option worth looking forward to, especially for patients who have failed previous treatments. With the deepening of research and the gradual expansion of indications, adagrasib is expected to become one of the standard treatment options for KRAS G12C mutation-related cancers in the future, making an important contribution to the development of precision medicine.

References：https://www.krazati.com/